Nexalin Technology, Inc. (NASDAQ: NXL ) on Thursday announced another publication of a peer-reviewed study in BMC Psychiatry related to the company's Deep Intracranial Frequency Stimulation (DIFS) technology.
Data Shows Reduction In Self-Injury And Depressive Symptoms
The data reported that Nexalin's DIFS 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with non-suicidal self-injury (NSSI) .
The study also reported measurable changes in brain-network activity and connectivity, providing additional neurophysiological evidence supporting Nexalin's non-invasive, high-power DIFS technology.
Evidence Supports Brain Network Changes
The analysis evaluated six female adolescent patients who received 21 days of 77.5 Hz, 15 mA stimulation using Nexalin's device .
The paper found changes in functional connectivity across emotional-control networks, including Default, Limbic, Salience/Ventral Attention, and Control networks.
The findings also showed improvement in anxiety and sleep quality measures.
No significant adverse effects were observed, with only one mild headache reported that resolved quickly.
The authors described the findings as preliminary evidence supporting further investigation in larger randomized controlled trials.
Nexalin Executives Highlight Mechanism And Market Potential
Mark White, CEO of Nexalin, added, "The Nexalin 15 mAmp DIFS technology allows for deeper penetration, which supports higher efficacy and enhanced treatment outcomes in a treatment-resistant population. In a market seeking safer, drug-free alternatives in mental health, each additional peer-reviewed publication helps further validate our technology and broaden its relevance across multiple indications."
In February, Nexalin launched its new AI-designed virtual clinic platform, NeuroCare, in collaboration with the University of California, San Diego.
The launch marked the first step in deploying Nexalin's digital health ecosystem, designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring across critical brain-health indications .
NXL Stock Price Activity: Nexalin shares closed at $0.35 on Wednesday, according to Benzinga Pro data .
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: News Health Care Top Stories Market-Moving Exclusives Exclusives General